

1 **Based on breast CEUS parameters combined with** 2 **serum CA153, a nomogram model was constructed to** 3 **predict the molecular classification of breastcancer**

4
5 Yanlei Ji¹, Zhen Han², Yong Zhang³, Wenwen Sun^{1*},

6
7 ¹Department of Ultrasound Medicine, Shandong Cancer Hospital and Institute,
8 Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,
9 Shandong Province 250117, China

10 ²Department of Internal Medicine, Jinan Second People's Hospital, Jinan, China. Jinan,
11 Shandong Province 250022, China

12 ³Department of Radiation Oncology, Shandong Cancer Hospital and Institute,
13 Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,
14 Shandong Province 250117, China

15
16 *Corresponding author: Wenwen Sun

17 telephone number : 18206413312

18 E-mail: sunwenwen419@163.com

19 Current Address: Shandong Cancer Hospital and Institute, Shandong First Medical
20 University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan,
21 Shandong

22

23

24

25

26

27

28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Abstract

30 Objective: To analyze the role of contrast-enhanced ultrasound (CEUS)
 31 parameters combined with serum tumor marker CA153 in the prediction of Breast
 32 Cancer (BC) molecular typing. Methods: From January 2020 to January 2023, 120
 33 BC patients diagnosed in our hospital were studied. According to the pathological
 34 results, the patients were divided into Luminal and non-Luminal BC groups. Both
 35 groups underwent contrast-enhanced ultrasound. The time-intensity curve (TIC) is
 36 obtained, and the relevant characteristic parameters are obtained, including peak
 37 intensity (PI), peak time (TTP), area under the curve (AUC), and mean transit time
 38 (MTT). Serum tumor marker CA153 was detected in both groups. Combined with
 39 CEUS characteristic parameters and serum CA153 of two groups of BC patients, a
 40 multiple Logistic regression model was constructed, and a nomogram prediction model
 41 was constructed based on the model. Calibration curve and receiver operating
 42 characteristic (ROC) curve were used to analyze the value of this model in the
 43 prediction of BC molecular classification. Results: There were no significant
 44 differences between Luminal BC patients and non-Luminal BC patients in clinical
 45 parameters and qualitative parameters of contrast-enhanced ultrasound, while there
 46 were statistical differences between quantitative parameters PI, AUC and serum tumor
 47 marker CA153. The AUC of the combined diagnosis of three parameters (PI, AUC and
 48 CA153) was significantly higher than that of the single index diagnosis group. The
 49 ROC curve AUC of BC molecular typing was predicted to be 0.94 based on the three-
 50 parameter nomogram, and the fitting of the actual curve and the ideal curve in the

calibration curve was close. Conclusions: The nomogram model based on breast contrast-enhanced ultrasound (CEUS) parameters combined with serum CA153 can effectively predict the molecular classification of BC.

Keyword: Breast Cancer, CEUS, ROC, CA153

Introduction

Breast Cancer (BC) is one of the most common malignant tumors in women. In recent years, its incidence has been increasing year by year and showing a trend of youth, and seriously threatening the life health and quality of life of patients^[1]. BC is a hormone-dependent tumor, and its carcinogenic risk is closely related to estrogen imbalance^[2-4]. Estrogen is mediated by estrogen receptor (ER) and progesterone receptor (PR) and its expression level is different in different BC patients, and its clinical manifestations, treatment and prognosis are also different^[5, 6]. Based on the expression status of ER and PR, BC is divided into Luminal type (positive for either ER or PR, including Luminal A and Luminal B) and non-Luminal type (negative for both ER and PR, including HER-2 and TN)^[7]. Therefore, the development of accurate diagnostic methods for BC patients with different molecular subtypes is very important for the treatment and prognosis of patients^[8]. In recent years, with the development of molecular biology technology, more tumor molecular markers related to BC have been discovered. Evaluating the expression levels of these markers in the serum of patients can provide valuable information for the occurrence, invasion and metastasis

sis of BC^[9]. Studies have suggested that carbohydrate antigen 153 (CA153), carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) have certain clinical value for BC screening, postoperative follow-up, recurrence and metastasis, especially CA153, which is the most valuable single diagnostic index with the best sensitivity, accuracy, positive predictive value and specificity^[10]. However, CA153 alone cannot accurately reflect the overall situation of the lesion. contrast-enhanced ultrasound (CEUS), as a non-invasive imaging technique, can observe the microcirculation in BC lesions. At the same time, it can fully reflect the information of the internal and peripheral tissue structure of the lesion^[11]. Based on this, the present study constructed a nomogram diagram with CEUS parameters combined with serum tumor marker index CA153 to predict different BC molecular typing, with a view to providing clinical reference for precise diagnosis and personalized treatment of BC.

86

87 **Materials and methods**

88 **1.1 Patients**

89 01/09/2024 searched the HIS information of our hospital, and selected 120 breast cancer patients diagnosed by examination from January 2020 ~ January 2023 as the research subjects. All patients underwent ultrasonography and clinical immunohistochemical pathology. Inclusion criteria: Invasive BC was confirmed by needle biopsy and immunohistochemical evaluation was performed; No chronic diabetes mellitus;

93

Patients volunteered to participate in the study; Complete medical records. Exclusion criteria: serious cardiovascular and cerebrovascular diseases and digestive tract diseases; Hypertension and autoimmune disease; Pregnancy or breastfeeding; Allergic to ultrasound contrast agent. This study was approved by the Ethics Committee of our hospital, and all patients have signed informed consent.

1.2 Contrast-enhanced ultrasound

GE Logiq E9 color Doppler ultrasonic diagnostic instrument, ML6-15 probe, frequency 9~15 MHz; Equipped with contrast-enhanced ultrasound imaging software. First, routine ultrasound was performed to observe the conditions of both mammary glands and determine the location of breast lesions to obtain better two-dimensional images. The optimal section was selected to cut into the angiography state, and 2.4 ml Sonovi (Bracco, Italy) was injected rapidly through the cubitus vein, and then rinsed with 5.0 ml 0.9% normal saline. The dynamic perfusion process of breast lesions was observed and recorded. The region of interest (diameter 4 mm, area 8 mm²) was selected when the breast lesions reached the peak of enhancement, and 5 points were selected from the inside and the edge of the lesions as the region of interest. The measured values of the region of interest at a total of 10 points were recorded and their mean values were taken. Start the QLAB analysis software to automatically analyze and obtain the time-intensity curve (TIC), and perform curve fitting to obtain the blood flow parameters of the region of interest: peak intensity (PI), peak time (TTP), area under the curve (AUC) and mean transit time (MTT). The above images were analyzed by two physicians. If

there were any differences in the diagnosis results, the third physician would participate in the discussion and get the final result after reaching an agreement.

1.3 Immunohistochemical examination

The expression levels of ER, PR, HER-2 and Ki-67 were detected in all BC samples after paraffin embedding and SP staining. ER, PR Rubric^[12]: ER and PR positive tumor nuclei $\geq 1\%$ positive, $< 1\%$ negative. HER-2 Rubric^[13]: Negative 1+ is HER-2 negative and 3+ is HER-2 positive; those with 2+ need to be tested by fluorescence in situ hybridization, in which those with gene amplification are HER-2 positive and those without amplification are HER-2 negative. Ki-67 proliferation index^[12]: Select the area with the highest staining density of tumor cells, and count the staining of 1000 cells. The number of positive cells/total cell count is the Ki-67 proliferation index.

1.4 CA153 detection and judgment criteria

2 mL of fasting venous blood was collected from both groups of patients in the early morning, and then centrifuged at 3000 r/min for 10 min after self-coagulation to separate the serum, which was stored in the refrigerator at -20°C for examination. Serum CA153 concentration was detected by using Abbott Architect 2000 automatic chemiluminescence immunoassay analyzer and special reagents. All operations were performed in strict accordance with the instrument and reagent instructions. The critical value of CA153 was 31.3 U/mL, and the assay was considered positive if the value exceeded the critical value.

1.5 Data analysis

All analyses were performed using R software version 4.0.2. Logistic regression and ROC analysis using R software. Measurement information data were expressed as Mean±SD and one-way ANOVA was used for comparison between groups. Count data were expressed as frequencies and χ^2 test was used. Receiver operating characteristic curves (ROC) were used to analyze the diagnostic performance of the model for different BC subtypes. $P<0.05$ was statistically significant.

Results

2.1 Clinical characteristics

The 120 study patients ranged in age from 24 to 80 years. There were 72 patients with Luminal BC and 48 patients with non-Luminal BC. The general data of the study patients included age, maximum mass diameter, menopause, pathological type, and pathological grade, and the results were shown in Table 1. There was no significant difference in the general data of 120 patients with different BC types.

Table 1 Clinical characteristics

| Molecular type | Age (years, mean±SD) | Maximum diameter (mm, mean±SD) | Menopause | | Pathological type | | | Histological grade | | |
|----------------|----------------------|--------------------------------|-----------|-----|---------------------------|----------------------------|--------|--------------------|----|-----|
| | | | N | Yes | invasive ductal carcinoma | invasive lobular carcinoma | others | I | II | III |

| | | | | | | | | | |
|-------------|------------|------------|-------|----|----|--------|----|----|-------|
| Luminal | 52.68±10.0 | 22.57±9.56 | 55 | 17 | 48 | 12 | 12 | 45 | 18 |
| Non-Luminal | 52.0±10.15 | 24.30±7.76 | 32 | 16 | 41 | 2 | 5 | 31 | 10 |
| χ^2/t | 0.3626 | 1.044 | 1.365 | | | 0.1950 | | | 0.059 |
| P | 0.7175 | 0.2985 | 0.243 | | | 0.9071 | | | 0.808 |

153

154 2.2 CEUS manifestations

155 The results of comparing the qualitative parameters of ultrasonography in patients
 156 with different BC subtypes are shown in Figure 1 and Table 2. In patients with the
 157 Luminal type, ultrasonography is dominated by centripetal hyperenhancement, with a
 158 predominantly rapid ascending and slow descending enhancement pattern, and unclear
 159 and enlarged enhancement with radiolucent convergence of the borders; Centripetal
 160 enhancement accounted for 14/39 patients with the non-Luminal type, with a
 161 predominantly rapid ascending and slow descending pattern of enhancement, unclear
 162 and enlarged borders after enhancement, and radiolucent convergence of the borders.

163

164 Figure 1 Contrast-enhanced ultrasound of different molecular types of BC

165 (A: Ultrasonography of a patient with Luminal B BC showing radial convergence around the periphery of the mass
 166 on ultrasonography; B: Ultrasonography of a patient with TN BC showing a well-defined and well-formed lesion
 167 on ultrasonography)

168

169

170 Table 2 Contrast-enhanced ultrasound findings of patients with different BC types

| Molecular type | enhancement mode | | | | | | | | | | Radial | | Enhance | | Perfusi | | | | | | | | | | | | |
|----------------|--------------------|-----|----------------------|---------|------------------|-----|--------|--------|----------|---------|--------|--------|---------|-------|---------|--------|----|---|---|--|----|--|-----|--|---|--|---|
| | Enhanced intensity | | Enhancement sequence | | enhancement mode | | d | | post-bou | | ndary | | conver | | d | | on | | | | | | | | | | |
| | Mole | | cular | | type | | slow g | | Rapid | | Rapid | | cle | | unc | | Ye | | N | | Eq | | enl | | Y | | N |
| | | Equ | lo | hi | offc | ent | dispe | rowth | growth | growth | cle | unc | Ye | N | Eq | arg | es | o | | | | | | | | | |
| | | al | w | gh | ente | ad | rsion | slow d | slow d | slow d | ar | lear | s | o | ual | e | | | | | | | | | | | |
| | | | | | | | | ecline | | ecline | | ecline | | | | | | | | | | | | | | | |
| Lumi | 18 | 1 | 39 | 17 | 32 | 23 | 12 | 56 | 4 | 14 | 58 | 49 | 2 | 19 | 53 | 44 | 2 | | | | | | | | | | |
| nal | 5 | | | | | | | | | | | | 3 | | | | 8 | | | | | | | | | | |
| Non- | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Lumi | 8 | 1 | 39 | 7 | 14 | 27 | 8 | 36 | 4 | 22 | 26 | 28 | 2 | 27 | 21 | 30 | 1 | | | | | | | | | | |
| nal | | | | | | | | | | | | | 0 | | | | 8 | | | | | | | | | | |
| x ² | 12.1607 | | | 11.9245 | | | 4.8137 | | | 10.4762 | | | 13.031 | | 14.6953 | 5.3785 | | | | | | | | | | | |
| | | | | | | | | | | | | | 9 | | | | | | | | | | | | | | |
| P | 0.058 | | | 0.063 | | | 0.5679 | | | 0.0649 | | | 0.054 | 0.062 | | 0.1460 | | | | | | | | | | | |

171

172 2.3 Comparison of CEUS characteristic parameter and

173 CA153

174 The CEUS quantitative parameters and serum CA153 indexes of patients

175 with different BC types were compared, The results are shown in Table 3. Th

ere were significant differences in PI, AUC and serum CA153 between Luminal
l and non-Luminal BC patients.

178

Table 3 Comparison of CEUS characteristic parameter and CA153

| Molecular type | PI(%) | TP(s) | AUC(%s) | MTT(s) | CA153(U/mL) |
|-------------------|-----------|-----------|--------------|-----------|--------------|
| Luminal | 37.50±2.2 | 23.18±2.2 | 1576.11±272. | 31.42±4.6 | 111.18±43.86 |
| Non-Luminal | 44.53±7.1 | 23.55±4.2 | 1907.74±340. | 32.42±5.2 | 84.57±39.30 |
| t | 6.600 | 0.541 | 5.961 | 1.112 | 3.401 |
| P | <0.001 | 0.589 | <0.001 | 0.269 | <0.001 |

180

2.4 Binary logistic regression analysis screened the independent predictors of BC molecular typing

To further evaluate the predictive performance of serum tumor marker CA153 and contrast-enhanced ultrasound parameters in different types of BC. Univariate regression analysis was performed to compare the clinical data, CEUS quantitative parameters and serum tumor marker CA153 between Luminal and non-Luminal subtypes. Subsequently, univariate factors with P values < 0.05 were included in the multivariate regression analysis, including CEUS parameters PI, AUC and serum tumor

189 marker CA153. Multivariate logistic regression analysis showed that PI, AUC and
190 CA153 were independent predictors of BC molecular typing ($P < 0.05$).(Table 4).

191 **Table 4 Binary logistic regression analysis screened the independent predictors of**
192 **BC molecular typing**

| Variate | Univariate regression analysis | | | Multivariate regression analysis | | |
|----------------------|--------------------------------|-----------|-------|----------------------------------|-------|---|
| | OR | 95%CI | P | OR | 95%CI | P |
| Age | 0.99 | 0.96,1.03 | 0.715 | - | - | - |
| Menopause | 1.47 | 0.65,3.33 | 0.355 | - | - | - |
| Maximum diameter | 1.02 | 0.98,1.07 | 0.297 | - | - | - |
| Histological grade | 0.79 | 0.33,1.90 | 0.597 | - | - | - |
| Enhanced intensity | 2.25 | 0.88,5.78 | 0.092 | - | - | - |
| Enhancement sequence | 2.73 | 0.97,7.71 | 0.058 | - | - | - |
| enhancement mode | 1.50 | 0.29,7.81 | 0.630 | - | - | - |

| | | | | | | |
|-------------------|------|----------|-------|------|----------|------|
| Enhanced post-bou | 0.29 | 0.13,0.6 | 0.103 | - | - | - |
| ndary | | 4 | | | | |
| Radial convergenc | 1.52 | 0.71,3.2 | 0.278 | - | - | - |
| e | | 5 | | | | |
| Enhanced range | 0.58 | 0.13,0.6 | 0.215 | - | - | - |
| | | 0 | | | | |
| Perfusion defect | 0.99 | 0.96,1.0 | 0.087 | - | - | - |
| | | 3 | | | | |
| PI | 1.36 | 1.20,1.5 | < | | 1.09,1.5 | 0.00 |
| | | 3 | 0.001 | 1.31 | 8 | 4 |
| TP | 1.04 | 0.92,1.1 | 0.542 | - | - | - |
| | | 6 | | | | |
| AUC | 1.01 | 1.01,1.0 | < | | 1.01,1.0 | 0.00 |
| | | 1 | 0.001 | 1.01 | 1 | 2 |
| MTT | 1.04 | 0.97,1.1 | 0.269 | - | - | - |
| | | 3 | | | | |
| CA153 | 0.98 | 0.98,0.9 | 0.002 | 0.98 | 0.96,0.9 | 0.00 |
| | | 9 | | | 9 | 1 |

193

194 **2.5 Construction of nomogram prediction model and**
195 **comparative analysis of prediction efficiency**

Based on the independent predictors (PI, AUC, CA153) of the three molecular subtypes of BC screened by binary logistic regression analysis, ROC curve was established to evaluate the accuracy of the combination of the three parameters in predicting non-Luminal BC (Figure 1). The results showed that the area under the curve (AUC) of the three-parameter model was 0.8307 (95%CI: 0.7437-0.9177), the sensitivity and specificity of the prediction were 75% and 94.44%, respectively, and the cut-off value of the prediction model was 0.3437. This indicates that the three-parameter combined prediction model of PI, AUC and serum CA153 has good predictive performance for the diagnosis of non-Luminal events (Table 5). Finally, we constructed a nomogram to predict the probability of non-Luminal BC based on the PI, AUC, and CA153 mentioned above (Figure 2). Each independent variable value corresponds to a score in the top row, and the scores of the individual independent variables are summed to obtain the total score, from which the probability is subsequently calculated. Finally, we used ROC curve and calibration curve to evaluate the predictive performance of the nomogram (Figure 3,4). The AUC of ROC curve was 0.94 (95%CI: 0.90-0.98). In the calibration curve, the actual curve was very close to the ideal curve. The nomogram has good predictive value for predicting the risk of non-Luminal BC.

Figure2 ROC curve was predicted by three-parameter combination

Table 5 Comparison of AUC values

| | AUC | 95%CI |
|----------|--------|---------------|
| PI | 0.8098 | 0.7163-0.9032 |
| AUC | 0.7590 | 0.6701-0.8478 |
| CA153 | 0.6780 | 0.5799-0.7760 |
| Combined | 0.8307 | 0.7437-0.9177 |

Figure 3 ROC curve of the nomogram model

Figure 4 Calibration curve of nomogram model

Discussion

BC is a highly vascular heterogeneous and malignant stromal tumor, and its incidence is increasing year by year, which has become the first disease seriously endangering women's health^[14]. The etiology of the disease is still unclear, and genetic factors and estrogen endocrine abnormalities are the main causes of the disease^[15]. In 2000, Perou et al^[16] first proposed that BC has different molecular subtypes, which can be divided into Luminal type and non-Luminal type (including HER-2 type and TN type). Studies have found that different molecular subtypes of BC have different biological behaviors, chemotherapy sensitivity and prognosis. Among them, Luminal BC is the most common molecular subtype, accounting for about 50%-70% of BC including Luminal A and Luminal B subtypes. Non-Luminal BC includes two different subtypes, HER-2 and TN subtypes, and this molecular subtype of BC is highly heterogeneous and characterized by high invasiveness. Compared with Luminal BC, it is more difficult

cult to diagnose and treat. Therefore, early detection, early diagnosis and early treatment of different molecular subtypes of BC are of great significance for improving the survival rate and quality of life of patients.

The occurrence, development, invasion and metastasis of BC are dependent on neovascular vessels. The marginal zone of tumor is an area with vigorous growth of tumor cells. The blood vessels are dense and densely distributed, anastomosing with each other to form loops, and some blood vessels are dilated in sinus shape^[17]. CEUS, as a non-invasive imaging method for preoperative evaluation of tumor angiogenesis, can accurately display blood perfusion compared with conventional ultrasound. The application of contrast-enhanced ultrasound can not only clearly observe the course and distribution of microvessels in the tumor, but also provide quantitative analysis of the tumor, providing imaging reference for the preoperative diagnosis and treatment of BC^[18]. In this study, we compared the characteristics of contrast-enhanced ultrasound between the two groups of patients. We found that the contrast-enhanced ultrasound of Luminal B C showed high enhancement, unclear boundary, radial convergence around the periphery, and expanded range after enhancement, and the enhancement pattern was mostly rapid increase and slow decrease. This result is the same as that of Wang Xiaoyan et al^[19], and can be used as a sensitive sign of Luminal BC. Non-Luminal BC showed high enhancement on contrast-enhanced ultrasound, and the boundary was basically unclear after enhancement, and the boundary did not significantly expand after enhancement, similar to the imaging characteristic

s of benign tumors, which was rare in other molecular subtypes, highlighting the heterogeneity of this subtype. Whether the quantitative parameters of contrast-enhanced ultrasound are correlated with the molecular subtypes of BC, many studies have conflicting conclusions^[20]. Lin Yun^[21] believes that there is a certain correlation between the quantitative parameters of contrast-enhanced ultrasound and in different molecular types of BC, and Jia Wanru^[22] believes that there is no statistically significant difference in the quantitative parameters of contrast-enhanced ultrasound between different molecular types of BC. In this study, we found that there were significant differences in PI and AUC of contrast-enhanced ultrasound in patients with different BC subtypes, which may have guiding significance for predicting different molecular types of BC.

At present, with the rapid development of genomics and molecular biology, different molecular subtypes of BC can better reflect the biological behavior of tumors. The detection of serum tumor markers can not only assist in diagnosis, but also effectively predict the efficacy, outcome and acquired drug resistance. CA153 is an antigen closely related to human breast malignant tumors. It was first found in BC epithelial cells as a variant of the epithelial surface glycoprotein of breast cells. When a cell undergoes cancerous transformation, the activation of glycosyltransferases causes changes in cell surface sugars and enters the blood with the tumor cells^[23]. It has obvious tumor specificity for BC and is of great significance for the early diagnosis of BC. The level of its serum content can be used as an index for the evaluation of the efficacy of BC^[24, 25], it is c

urrently clinically recognized as a more specific tumor marker for the diagnosis of BC. In this study, we found that the serum CA153 level was significantly higher in Luminal subtype patients than in non-Luminal subtype patients. Therefore, we hypothesized that the serum CA153 difference in different BC subtypes combined with CEUS related parameters could help us to better predict the molecular subtype of BC. Based on this, we used multivariate Logistic regression to analyze the clinical data, contrast-enhanced ultrasound characteristic parameters and serum CA153 of the two groups of patients. The results showed that the quantitative parameters of contrast-enhanced ultrasound PI, AUC and serum CA153 were independent predictors of BC molecular typing. The ROC curve was used to compare the efficacy of PI, AUC, CA153 single parameters and the combination of three parameters in the diagnosis of BC molecular typing, and the results showed that the AUC of the combination of three parameters was significantly higher than that of each parameter. Then we constructed a nomogram prediction model using three parameters, and evaluated the predictive performance of the model using ROC curve and calibration curve. The results of ROC curve and calibration curve showed that the nomogram had good predictive value for the risk of non-Luminal BC.

In conclusion, the ultrasonographic features of BC can reflect the biological characteristics of different BC molecular typing and are closely associated with the serum tumor marker CA153. In this study, the ultrasonographic parameters of PI, AUC and serum CA153 were used to construct a columnar graphical

model to effectively predict the molecular typing of BC, which can provide certain clinical references for accurate diagnosis and personalized treatment of BC. However, this study is a single-center retrospective analysis with a limited sample size, which did not explore the specific molecular typing of BC and lacked external data validation, so it needs to be further improved.

Author contributions

Yanlei Ji, Zhen Han, and Yong Zhang: study design, data analysis and interpretation, and manuscript revision. Wenwen Sun: manuscript drafting. All the authors of this study read and approved the final manuscript.

Funding

No funding was granted for this study.

Competing interests

Authors declare no competing interests.

330

331

332

333

334

335

336

References

- [1] Zhi B, Yu J Q, Lv S Q. To establish a multi-parameter model to predict early triple-negative breast cancer (TNBC)[J]. Radiologic Practice, 2021,36(8):1021-1025.DOI: 10.13609/j.cnki.1000-0313.2021.08.014
- [2] Burstein H J. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer[J]. N Engl J Med, 2020,383(26):2557-2570.DOI: 10.1056/NEJMra1307118
- [3] Clusan L, Le Goff P, Flouriot G, et al. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses[J]. Int J Mol Sci, 2021,22(2).DOI: 10.3390/ijms22020756
- [4] Valko-Rokytovska M, Ocenas P, Salayova A, et al. Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics[J]. Int J Mol Sci, 2021,22(11).DOI: 10.3390/ijms22115878
- [5] Farcas A M, Nagarajan S, Cosulich S, et al. Genome-Wide Estrogen Receptor Activity in Breast Cancer[J]. Endocrinology, 2021,162(2).DOI: 10.1210/endocr/bqaa224
- [6] Derakhshan F, Reis-Filho J S. Pathogenesis of Triple-Negative Breast Cancer[J]. Annu Rev Pathol, 2022,17:181-204.DOI: 10.1146/annurev-pathol-042420-093238
- [7] Rella R, Belli P, Giuliani M, et al. Automated Breast Ultrasonography (ABUS) in the Screening and Diagnostic Setting: Indications and Practical Use[J]. Acad Radiol, 2018,25(11):1457-1470.DOI: 10.1016/j.acra.2018.02.014
- [8] Subramanian S, Keating N L. Delays in breast cancer diagnosis after a state policy limiting Medicaid enrollment[J]. Cancer, 2017,123(17):3219-3221.DOI: 10.1002/cncr.30769
- [9] Bidard F C, Hajage D, Bachelot T, et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study[J]. Breast Cancer Res, 2012,14(1):R29.DOI: 10.1186/bcr3114
- [10] Li X, Xu Y, Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases[J]. Prog Mol Biol Transl Sci, 2019,162:265-276.DOI: 10.1016/bs.pmbts.2019.01.005
- [11] Ji C L, Li X L, He Y P, et al. Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: The correlation with pathological prognostic factors[J]. Clin Hemorheol Microcirc, 2017,66(4):333-345.DOI: 10.3233/CH-170251
- [12] National Health Commission Of The, S Republic Of China. Breast Cancer Guidelines (2022 edition)[J]. China Licensed Pharmacist, 2022,19(10):1-26
- [13] Liu Y P, Bu H, Yang W T. Chinese breast cancer HER2 detection guidelines update interpretation (2019 edition)[J]. Chinese Journal of Pathology, 2019,48(3):182-185.DOI: 10.3760/cma.j.issn.0529-5807.2019.03.004
- [14] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3):209-249.DOI: 10.3322/caac.21660
- [15] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953. DOI: 10.1002/ijc.31937
- [16] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000,406(6797):747-752.DOI: 10.1038/35021093

- [17] Bian X W, Jiang X F, Chen J H, et al. Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas[J]. Int Immunopharmacol, 2006,6(1):90-99.DOI: 10.1016/j.intimp.2005.08.004
- [18] Claudon M, Dietrich C F, Choi B I, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS [J]. Ultraschall Med, 2013,34(1):11-29.DOI: 10.1055/s-0032-1325499
- [19] Wang X Y, Kang L K, Lan C Y et al. Characteristics and diagnosis of breast malignant masses by contrast-enhanced ultrasound[J]. Chinese Journal of Ultrasonography, 2012,28(08):705-708
- [20] He J. The application value of contrast-enhanced ultrasound in the diagnosis of breast tumors [J]. Journal of Clinical Ultrasound in Medicine, 2017,19(7):471-473
- [21] Lin Y. Journal of Clinical Ultrasound in Medicine[D]. Guangxi Medical University, 2014.
- [22] Jia W R. Study on contrast-enhanced ultrasound based on different molecular subtypes of breast cancer[D]. Shanghai Jiao Tong University, 2015.
- [23] Wang B T. The application value of serum tumor markers combined with dynamic detection in the diagnosis and monitoring of breast cancer[D]. Qingdao University, 2021.
- [24] Ghadge M S, Naik P P, Tiwari B P, et al. A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma[J]. Indian J Clin Biochem, 2012,27(1):97-99.DOI: 10.1007/s12291-011-0168-5
- [25] Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer[J]. Int J Mol Sci, 2014,15(6):9546-9565.DOI: 10.3390/ijms15069546











